NCT03106532

Evaluation of PHP-201 Ophthalmic Solution in Patients With Normal Tension Glaucoma

A Multicenter, Randomized, Placebo-controlled, Double-blind, Dose-finding Phase 2 Clinical Trial to Evaluate the Efficacy in Reduction of Intraocular Pressure and Safety of PHP-201 in Patients With Normal Tension Glaucoma

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 119 (actual)
• Sponsor: pH Pharma · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

Evaluation of the optimal dose for the efficacy in reduction of intraocular pressure and safety of PHP-201 ophthalmic solution in patients with normal tension glaucoma

Detailed description

Data collection (electronic case report forms), Data dictionary (MedDRA)

Conditions

• Normal Tension Glaucoma

Interventions

Type	Name	Description
DRUG	PHP-201 0.25% ophthalmic solution	3 drops daily, 28 days
DRUG	PHP-201 0.5% ophthalmic solution	3 drops daily, 28 days
DRUG	Placebo ophthalmic solution	3 drops daily, 28 days

Timeline

• Start date: 2017-03-06
• Primary completion: 2018-05-02
• Completion: 2018-05-02
• First posted: 2017-04-10
• Last updated: 2018-10-26

Locations

1 site across 1 country: South Korea